Bone Loss after Stopping Estrogen or Alendronate Therapy
Journal: Annals of Internal Medicine (2002)

Summaries for Patients3 December 2002Bone Loss after Stopping Estrogen or Alendronate TherapySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-11-200212030-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Less dense and more fragile bones (osteoporosis) occur as people age. This is a big problem because bone fractures after falls or injuries happen more easily in older people with osteoporosis. There are several ways to help prevent fragile bones and fractures from osteoporosis. Adequate calcium and vitamin D intake, exercise, and avoidance of alcohol and tobacco prevent bone loss. Doctors also give drugs, such as estrogen or bisphosphonates, to prevent more bone loss in people who already have osteoporosis. Many people have difficulty taking the drugs for ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis. A Randomized, Double-Blind, Placebo-Controlled Trial.” It is in the 3 December 2002 issue of Annals of Internal Medicine (volume 137, pages 875-883). The authors are SL Greenspan, RD Emkey, HG Bone III, SR Weiss, NH Bell, RW Downs Jr., C McKeever, SS Miller, M Davidson, MA Bolognese, AL Mulloy, N Heyden, M Wu, A Kaur, and A Lombardi.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSignificant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis Susan L. Greenspan , Ronald D. Emkey , Henry G. Bone III , Stuart R. Weiss , Norman H. Bell , Robert W. Downs Jr. , Clark McKeever , Sam S. Miller , Michael Davidson , Michael A. Bolognese , Anthony L. Mulloy , Norman Heyden , Mei Wu , Amarjot Kaur , and Antonio Lombardi Metrics 3 December 2002Volume 137, Issue 11Page: I-31KeywordsBoneBone fractureBone resorptionDrug therapyDrugsEstrogen replacement therapyEstrogensOsteoporosisUterusVitamin D ePublished: 3 December 2002 Issue Published: 3 December 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...